Toward an observatory of the evolution of clinical trials through phylomemy reconstruction: the COVID-19 vaccines exampleResearch article Published on 2022-09-012022-10-05 Journal: Journal of clinical epidemiology [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, [키워드] analyzed approach automatically booster clinical clinical trial clinical trials Co-word analysis Community Complete COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccine trial COVID-19 vaccine trials curated description descriptions Efficacy epidemiologists Evolution example FIVE Heterologous homologous identify implementation Interaction knowledge Knowledge dynamics objective Phylomemy platform produced provide reconstructed Registered registry Research Result setting Structure Trial vaccination Vaccine World Health Organization [DOI] 10.1016/j.jclinepi.2022.05.004 [Article Type] Research article
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of ConcernArticle Published on 2022-08-302022-11-15 Journal: mBio [Category] SARS, 변종, 진단, [키워드] active against addition Adults anti-SARS-CoV-2 anti-SARS-CoV-2 immune responses approved booster booster dose Brazil CD4 cellular Chilean China clinical trial concern CoronaVac COVID-19 Delta dose doses Emergency use healthy healthy volunteers homologous humoral immune response Immunity immunized IMPROVE inactivated Inactivated vaccine increase interferon neutralizing antibody not significantly different omicron phase phase III clinical trial. previous study reached reduced reported SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2-specific T cell second dose secretion shown significant increase significantly T cell T cell activation T cell response the vaccine these cell Turkey vaccination schedule Vaccine variants of concern VoC VOCs were assessed WHO World Health Organization [DOI] 10.1128/mbio.01423-22 PMC 바로가기
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-AnalysisArticle Published on 2022-08-292022-11-15 Journal: International Journal of Environmental Research an [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome antibody booster booster dose Cohort studies collaboration coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccine effective Effectiveness evaluate events fatigue Fever geometric GMTs help heterogeneous Heterologous heterologous booster dose higher risk homologous homologous booster dose Hospital admission immunogenicity interferon malaise myalgia neutralizing antibody Neutralizing titer Odds ratio outcome public health reduce resource review Safety SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant searched suggested symptomatic the vaccine vaccination Vaccine Vaccines variance model were used [DOI] 10.3390/ijerph191710752 PMC 바로가기
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccinesArticle Published on 2022-08-262022-11-16 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] addition asymptomatic infection BNT162b2 booster Breakthrough infection caused comprehensive analysis COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines COVID-19-related death cumulative Delta delta variant effective Effectiveness Efficacy ENhance heterogenous homologous immunization incidence Infection interval less mRNA-1273 omicron Prevent PROTECT SARS-CoV-2 SARS-COV-2 infection severe COVID-19 symptomatic the SARS-CoV-2 vaccination Vaccine variant variants [DOI] 10.3389/fimmu.2022.945930 PMC 바로가기
IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease SeverityArticle Published on 2022-08-262022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 진단, [키워드] acute respiratory syndrome Against anti-S anti-S antibody anti-S2 anti-SARS-CoV-2 antibody Anti-spike antibody Antibody Response bidirectional cohorts common cold common cold human coronaviruses (HCoVs) coronavirus correlated COVID-19 cross-react cross-reactive antibody cross-reactive antibody response decrease disease disease severity domain Effect elicited HKU1 homologous Human human coronavirus IgG IgG antibody immune immune imprinting. Immunoglobulin morbidity and mortality Multiplex assay OC43 Organ failure Protective RaTG13 recognizing response S proteins S1-reactive antibodies SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection sera serum sample severe coronavirus disease Severity of disease significantly increased SOFA spike strain subject with COVID-19 [DOI] 10.1093/infdis/jiac022 PMC 바로가기
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variantsArticle Published on 2022-08-252022-11-15 Journal: eLife [Category] SARS, 변종, 진단, [키워드] antibody BBIBP-CorV booster Breakthrough infection broad-spectrum circulating variants combating COVID-19 COVID-19 vaccine cross-neutralizing antibody develop effective elicited homologous immunogenic immunology inactivated indicate induce Infectious disease Inflammation Microbiology Mutation neutralization omicron Omicron variant pandemic Population RBD SARS-CoV-2 SARS-CoV-2 variant spike receptor-binding domain Test trimeric Vaccine vaccine candidate Vaccines variants viruses with COVID-19 [DOI] 10.7554/eLife.78633 PMC 바로가기
Evidence for deleterious effects of immunological history in SARS-CoV-2SARS-CoV-2에서 면역학적 병력의 유해한 영향에 대한 증거Article Published on 2022-08-242022-09-11 Journal: PLoS ONE [Category] SARS, 진단, 치료법, [키워드] Amino acid amino acid change antibodies binding antibody Antigen antigenic association binding binding assay Binding assays blood sample COVID-19 disease COVID-19 disease severity COVID-19 infections cross-reactive cross-reactivity deleterious effect demonstrated epitope H3N2 hallmark hallmarks homologous identify IgG immunological Immunological memory Infection Influenza influenza A influenza A virus influenza infection influenza strain influenza vaccine Injury Patient presence of antibody Protein SARS-CoV-2 SARS-CoV-2 nucleocapsid sequence severe COVID-19 infections underlie upregulation Vaccine widespread [DOI] 10.1371/journal.pone.0272163 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial6세 이상의 건강한 참가자를 대상으로 한 상동 프라임-부스트 요법을 사용한 재조합 아데노바이러스 5형 벡터 코로나바이러스 질병 2019(COVID-19) 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 2b상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, 치료기술, [키워드] Ad5-vectored COVID-19 vaccine Adenovirus adenovirus type-5-vectored COVID-19 vaccine Adults Adverse adverse events antibody Antibody Response boost children clinical Cohort coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose double-blind elicited ELISA enrolled enzyme enzyme-linked immunosorbent assay event geometric mean geometric mean titer geometric mean titers GMT GMTs healthy homologous homologous prime immune response immune responses immunogenicity increasing age MIN neutralizing antibody participant phase phase 2b trial. Placebo placebo-controlled trial prime-boost regimen pseudovirus neutralizing antibody Randomized RBD receiving Receptor binding domain recombinant recombinant adenovirus robust Safe Safety SARS-CoV-2 single dose tolerable Trial vaccination Vaccine Viral viral particle [DOI] 10.1093/cid/ciab845 PMC 바로가기 [Article Type] Randomized Controlled Trial
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19COVID-19에 대한 이종 또는 동종 ChAdOx1nCoV-19/BNT162b2 백신 접종 후 6개월 후 BNT162b2로 강화된 면역 반응Article Published on 2022-08-182022-09-11 Journal: Nature Communications [Category] SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] Alpha anti-Spike IgG approach B.1.1.529 Beta BNT BNT162b2 both groups CD4 CD8 Cell ChAd choice compensated delta variant Delta variants Effect followed by Frequency Gamma Heterologous homologous immune response immune responses Immunity in both groups increase in moderate mRNA vaccine Neutralizing activity Neutralizing antibody response neutralizing antibody responses omicron protective immunity repeated reported SARS-CoV-2 second vaccination subsequent T cell vaccinated individual vaccinated individuals vaccination vaccination against COVID-19 Vaccine variant virus [DOI] 10.1038/s41467-022-32527-2 PMC 바로가기 [Article Type] Article
Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaquesArticle Published on 2022-08-172022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] Activation Adenovirus adenovirus vectored vaccine animal model animal models antibody booster caused COVID-19 COVID-19 vaccine demonstrated effective Effectiveness expressing Heterologous heterologous immunization homologous immunization Inactivated vaccine Invasion Lung injury macaque mice Neutralizing activity NHP NHPs non-human primate omicron priming PROTECT Protective protective effectiveness. reduced regimen Regulation risk SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variant SARS-CoV-2 variants spike-specific antibody response T cell T cell response upregulating vaccination Vaccine-induced immunity variant virus was tested [DOI] 10.3389/fimmu.2022.949248 PMC 바로가기